# Life Sciences Strategy Canonical URL: https://digital-acquis.eu/initiative/life-sciences-strategy Entry type: initiative Source edition current through: 17 July 2026 (2026-07-17). This is not a page modification date. Status: delivered. A delivered initiative is not necessarily legislation in force. Instrument: Communication Date as recorded: 02 Jul 2025 Date kind: date Status note: full date links only to published artifact types ## Summary The Life Sciences Strategy addresses fragmented funding and innovation systems, regulatory complexity and slow market uptake. Its actions include the Biotech Act, coordinated work on new biomedical research methods, a research and innovation agenda for food systems, and a data assembly for cross-regulatory cooperation. The Commission presents these measures as support for innovation, economic growth and job creation in European life sciences. ## Sources - [Official source]() - [Official source]() ## Action items (36; complete published list) ### 1. Action item 380001 (Flagship) The Commission will propose an investment plan for clinical research to facilitate funding for multi-country clinical trials, in compliance with competition rules, and to further develop and streamline European research infrastructures in the field of clinical research. Provenance: source document doc-043, paragraph 1. Digital dimension: no. ### 2. Action item 380002 (Flagship) The Commission will create a network of European Centres of Excellence in advanced therapy medicinal products (ATMPs) to coordinate their further development, together with the Member States, taking into account existing centres, with EUR 4 million financial support from the Horizon Europe work programme 2026-202754 Provenance: source document doc-043, paragraph 2. Digital dimension: no. ### 3. Action item 380003 The Commission will continue to support, monitor and evaluate the implementation of the Clinical Trials Regulation with the overall aim to make Europe more competitive for clinical trials and medical research investments. Provenance: source document doc-043, paragraph 3. Digital dimension: no. ### 4. Action item 380004 The Commission will launch a pilot for phased, stepwise funding of collaborative research under the Horizon Europe work programme 2026-202755, leveraging results from past EU projects, to accelerate the development of promising health technologies. Provenance: source document doc-043, paragraph 4. Digital dimension: no. ### 5. Action item 380005 The Commission will explore a pilot to identify and exploit collaboration opportunities between EU Biotech clusters across the EU, with a focus on supporting the scaling-up of their startups as well as on enhancing their global industrial innovation standing. The action should build upon existing actions, such as the European Cluster Collaboration Platform. Provenance: source document doc-043, paragraph 5. Digital dimension: no. ### 6. Action item 380006 (Flagship) The Commission will promote One Health approaches in research and innovation by collaborating with Member States and other stakeholders to: Provenance: source document doc-043, paragraph 6. Digital dimension: no. ### 7. Action item 380007 identify further priority areas that would benefit from One Health approaches for consideration for financial support, leveraging existing data and repositories, and Provenance: source document doc-043, paragraph 7. Digital dimension: no. ### 8. Action item 380008 develop guidance to support inter- and transdisciplinary R&I in One Health. Provenance: source document doc-043, paragraph 8. Digital dimension: no. ### 9. Action item 380009 (Flagship) The Commission ambitions to make the EU a world-class innovator in One Health microbiome-based solutions, including by mobilising close to EUR 100 million under the Horizon Europe work programmes for 2026-2027 to support development and deployment of such solutions. Provenance: source document doc-043, paragraph 9. Digital dimension: no. ### 10. Action item 380010 (Flagship) The Commission will implement the new strategic research and innovation agenda on health and climate change, including through mobilising EUR 170 million Horizon Europe funding and invites Member States and industry to contribute.The Commission will also propose a global research collaboration to foster alignment between global funders and to support the development of solutions to increase our resilience and to support climate adaptation and mitigation. Provenance: source document doc-043, paragraph 10. Digital dimension: no. ### 11. Action item 380011 The Commission will develop a strategic R&I agenda on food systems to foster development of competitive, sustainable and resilient food systems solutions, complementing the forthcoming strategic approach to R&I in agriculture, forestry and rural areas announced in the Vision for agriculture and food64 Provenance: source document doc-043, paragraph 11. Digital dimension: no. ### 12. Action item 380012 (Flagship) The Commission will establish a European Life Sciences R&I Data Assembly bringing together a range of EU and Member State authorities working in data-related domains and key EU R&I bodies to support consistent interpretation and harmonisation of relevant legal data frameworks and to strengthen cross-regulatory coordination and collaboration. Provenance: source document doc-043, paragraph 12. Digital dimension: no. ### 13. Action item 380013 The Commission will support activities to develop and populate strategic biodata resources, including non-human biodata, and enable access for European and global users in complement to the European Data Union strategy. Provenance: source document doc-043, paragraph 13. Digital dimension: no. ### 14. Action item 380014 The Commission will invest EUR 50 million in integration of multi-modal generative AI technologies into multidisciplinary biomedical research via the Horizon Europe Work Programme 2025. Provenance: source document doc-043, paragraph 14. Digital dimension: no. ### 15. Action item 380015 The Commission will invest EUR 25 million from the Digital Europe work programme 2026 to boost the European genomic data infrastructure, in alignment with the EHDS. Provenance: source document doc-043, paragraph 15. Digital dimension: no. ### 16. Action item 380016 The Commission will support research and innovation in cross-sectoral life science technologies to develop new products that can drive industrial innovation and sustainability (including novel molecules and advanced materials), improve the efficiency of biomanufacturing and other industrial biotechnology processes, and support bioremediation. This includes mobilising EUR 200 million under the Horizon Europe work programme 2026-2027. Provenance: source document doc-043, paragraph 16. Digital dimension: no. ### 17. Action item 380017 The Commission will support the scale-up and uptake of sustainable advanced fermentation by promoting innovation through public-private partnerships and supporting the scaling-up of startups and other SMEs operating in this area and by organising an annual conference on advanced fermentation to connect stakeholders, foster collaboration and promote knowledge exchange. Provenance: source document doc-043, paragraph 17. Digital dimension: no. ### 18. Action item 380018 The Commission will support life sciences research and innovation to promote the leadership position of the European Union for bioeconomy solutions and sustainable management of biomass. This includes mobilising more than EUR 150 million under the Horizon Europe work programme 2026-2027. Provenance: source document doc-043, paragraph 18. Digital dimension: no. ### 19. Action item 380019 The Commission will collaborate with Member States, industry, academia and regulators to support development, validation and uptake of new approach methodologies to de-risk the development of new medicinal products and medical devices through a new European Research Area (ERA) policy action85 . In addition, the Horizon Europe programme will allocate EUR 50 million to these methodologies through its work programme 2026-2027. Provenance: source document doc-043, paragraph 19. Digital dimension: no. ### 20. Action item 380020 The Commission will continue to support the emergence and adoption of the next generation of virtual human twins solutions in the context of the European Virtual Human Twins Initiative. The Commission will dedicate EUR 8 million for a Virtual Human Twins Incubator to support uptake of virtual human twin solutions in the European market and their use in clinical research (e.g. clinical trials, clinical investigations) through the Digital Europe Work Programme 2025-2027. Provenance: source document doc-043, paragraph 20. Digital dimension: no. ### 21. Action item 380021 (Flagship) The Commission will take action to support the career development of life science researchers and to help researchers from non-EU countries set up in the EU, including through the 'Choose Europe’ initiative, and work in synergy with similar activities run by the Member States Provenance: source document doc-043, paragraph 21. Digital dimension: no. ### 22. Action item 380022 The Commission will launch a foresight study to identify the competences, skills and training needs for the life sciences, including for optimising the uptake of artificial intelligence. With EUR 1 million financial support from the Horizon Europe work programme 2026-2027, the study will complement relevant data and analysis by the European Skills Intelligence Observatory. Provenance: source document doc-043, paragraph 22. Digital dimension: no. ### 23. Action item 380023 (Flagship) The Commission will propose an EU Biotech Act to make the EU regulatory system more conducive to biotech innovation in various biotech sectors, alongside supportive measures. Provenance: source document doc-043, paragraph 23. Digital dimension: no. ### 24. Action item 380024 (Flagship) The Commission will be ready to propose legislation that strikes a balance between simplifying EU regulations related to medical devices and in vitro diagnostics, with a view to facilitate businesses’ operations across the EU single market, and effectively protecting patient safety and public health. Provenance: source document doc-043, paragraph 24. Digital dimension: no. ### 25. Action item 380025 The Commission will create an AI-powered interactive tool to help researchers and innovators navigate the EU regulatory landscape, particularly in the early stages of research and development. Provenance: source document doc-043, paragraph 25. Digital dimension: no. ### 26. Action item 380026 (Flagship) To fast-track life science startups in their journey to the market,the Commission will launch a matchmaking strategic interface connecting life science startups, industry and investors, leveraging the EIC’s portfolios, the EIC’s Trusted Investors Network (TIN) and other key European stakeholders. Provenance: source document doc-043, paragraph 26. Digital dimension: no. ### 27. Action item 380027 The Commission will, through Horizon Europe and EU4Health, stimulate the procurement of life science innovation through dedicated calls in areas such as adaptation to climate change, next-generation vaccines or affordable solutions for cancer, backed by funding of approximately EUR 300 million107. Provenance: source document doc-043, paragraph 27. Digital dimension: no. ### 28. Action item 380028 The Commission will mobilise EUR 2 million financial support from the Horizon Europe work programme 2026-2027 to support life science stakeholders and policy makers in public outreach by setting up a repository of tools and best practices in responsible R&I, risk and science communication, and pilot public outreach measures. Provenance: source document doc-043, paragraph 28. Digital dimension: no. ### 29. Action item 380029 (Flagship) The Commission will reinforce the coordination of its services and set up a ‘Life Science Coordination Group’ within the Commission to ensure innovation- friendly coherent policies, funding and activities. The Coordination Group will also: Provenance: source document doc-043, paragraph 29. Digital dimension: no. ### 30. Action item 380030 organise high-level topical discussions between policy makers and stakeholders; Provenance: source document doc-043, paragraph 30. Digital dimension: no. ### 31. Action item 380031 monitor progress in implementing this strategy; Provenance: source document doc-043, paragraph 31. Digital dimension: no. ### 32. Action item 380032 manage the European Life Science R&I Data Assembly; Provenance: source document doc-043, paragraph 32. Digital dimension: no. ### 33. Action item 380033 support the development of an interactive tool to help European researchers and innovators navigate the life science regulatory landscape and provide information on data services and tools; Provenance: source document doc-043, paragraph 33. Digital dimension: no. ### 34. Action item 380034 organise and manage other activities, such as: Provenance: source document doc-043, paragraph 34. Digital dimension: no. ### 35. Action item 380035 creating a stakeholder forum for life sciences to encourage broad dialogue and engagement; Provenance: source document doc-043, paragraph 35. Digital dimension: no. ### 36. Action item 380036 developing and coordinating horizon-scanning capabilities to identify promising emerging technologies with high potential for life sciences. Provenance: source document doc-043, paragraph 36. Digital dimension: no. ## Referenced entries - [European Research Area (ERA)]() — status: not recorded. Source document doc-043, action item 380019: > The Commission will collaborate with Member States, industry, academia and regulators to support development, validation and uptake of new approach methodologies to de-risk the development of new medicinal products and medical devices through a new European Research Area (ERA) policy action85 . In addition, the Horizon Europe programme will allocate EUR 50 million to these methodologies through its work programme 2026-2027. - [European Data Union Strategy]() — status: delivered. The strategy will establish a simpler, coherent EU framework for secure, large-scale data sharing between businesses and public administrations to power AI. It will align and streamline existing rules and practices, strengthen cross-border interoperability, and embed robust safeguards for confidentiality, integrity, security and IP. Concretely, it will: promote common technical and semantic standards (e.g. schemas, metadata, APIs); enable trusted data intermediaries and data-pooling mechanisms; expand access via privacy-preserving methods (e.g. anonymisation, synthetic data, secure processing); and clarify fair, transparent licensing for B2B and public-private data use. Closely linked to AI Factories, new Data Labs will federate sectoral datasets and connect to Common European Data Spaces to unlock high-quality training data at scale. Source document doc-043, action item 380013: > The Commission will support activities to develop and populate strategic biodata resources, including non-human biodata, and enable access for European and global users in complement to the European Data Union strategy. ## Citing documents - [Political Guidelines 2024-29]() — status: not recorded. The Political Guidelines link European competitiveness with industrial renewal, digital innovation and simpler rules for businesses. They propose support for AI, data sharing, biotechnology and strategic investment, alongside cleaner energy, circular production and changes to public procurement. A Union of Skills would connect education, training and recognition of qualifications across borders. The programme also covers hospital cybersecurity, protection against online manipulation and harmful platform design, and measures to improve working conditions. International partnerships and economic security form part of this agenda, while institutional reforms and stronger cooperation on lawmaking are intended to support its implementation. Source document doc-002, action item 30022: > In order to make it easier to bring biotech from the laboratory to factory and then onto the market we will propose a new European Biotech Act in 2025. This will be part of a broader Strategy for European Life Sciences to look at how we can support our green and digital transitions and develop high-value technologies. - [Competitiveness Compass]() — status: not recorded. The Competitiveness Compass brings together work on innovation, industrial transition and the conditions for businesses to grow in Europe. Its agenda spans startups, strategic technologies, research and investment, alongside affordable energy, cleaner industry and circular production. Measures on the Single Market, simpler rules, procurement and standardisation accompany this sectoral work. The programme also includes trade partnerships, raw-material supplies, security and preparedness. Skills, labour mobility and quality jobs connect the economic agenda with workforce needs. The programme combines strategies, legislative proposals, investment initiatives and coordination measures across these policy areas. Source document doc-019, action item 180009: > Life Sciences Strategy [Q2 2025] - [Startup and Scaleup Strategy]() — status: not recorded. The strategy aims to make it easier for innovative companies to start, grow and operate across Europe. It combines simpler company rules and digital administration with better access to finance, markets, talent and research infrastructure. Proposed measures include the 28th regime, the European Business Wallet, regulatory sandboxes and support for deep-tech investment. Work on research commercialisation, intellectual property and procurement is intended to help ideas reach customers. Talent initiatives address education, mobility and recruitment, while common definitions, a scoreboard and an annual founder survey would track changes in the startup and scaleup environment. Source document doc-035, action item 330005: > The Commission will put forward proposals to reduce regulatory burdens in strategic sectors through forthcoming sectoral legislative and non-legislative proposals, such as the EU Biotech Act, the EU Bioeconomy Strategy, the EU Life Science Strategy, the Advanced Materials Act the Medical Devices Regulation and the Omnibus Defence Simplification Package (as of 2025). - [Apply AI Strategy]() — status: delivered. Source document doc-051, action item 430001: > establish European AI-powered advanced screening centres to accelerate the introduction of innovative tools for prevention and diagnosis making in healthcare facilities and bringing healthcare services to underserved areas. The initiative aims to improve early detection and ensure timely diagnosis, in particular for cardiovascular diseases and cancer. It will pursue an approach to ensure that AI-powered screening and diagnosis take into account gender-specific factors. By deploying AI solutions, these centres will support real-world clinical validation and local performance testing and generate evidence for clinical adoption. The network of these AI-powered centres will facilitate access to high-quality datasets building on the European Health Data Space as well as the European digital infrastructures for the cancer imaging and genomic data, and support testing and validation of promising AI models including for personalised prevention. This will build on the relevant actions under the Europe’s Beating Cancer Plan, Life Sciences Strategy and the forthcoming EU Cardiovascular Health Plan. ## Current developments Latest updates from Digital Policy Alert and Global Trade Alert. No reviewed developments available; this does not establish that no developments exist. ## Associated policy priorities - [Research, Technology & Industrial Capacity]() ## Broader policy context (shared priority; not a direct citation) - [Advanced Materials Act]() — status: forthcoming. Europe’s competitiveness in the green and digital transitions will depend on its ability to develop, produce and deploy next-generation materials at scale. To achieve this, the Commission will propose an Advanced Materials Act establishing clear framework conditions for the entire value chain; from fundamental research and prototyping to manufacturing and market uptake. The Act will focus on accelerating industrialisation, de-risking private investment and securing resilient supply chains for materials critical to clean technologies, energy, defence and space. By providing a coherent strategic framework, it aims to reduce dependencies, boost technological sovereignty and position Europe as a global leader in advanced materials innovation. - [Charter of Access for Industrial Users to Research and Technology Infrastructures]() — status: forthcoming. This initiative will standardise and simplify industrial access to Europe’s research and technology infrastructures so innovators can prototype, test and scale faster. It will set common, transparent access and contractual terms (e.g. IP use, pricing, liability, data handling) across borders and introduce a streamlined entry point for companies, including startups and scaleups. Linked to the AI Factories ecosystem, the Charter will be backed by dedicated EU support to make AI computing facilities affordable for SMEs. Complementary guidance will clarify how universities and public research organisations can grant access under State aid rules. Together, these measures cut fragmentation, lower transaction costs and speed time-to-market. - [EU Bioeconomy Strategy]() — status: delivered. The EU Bioeconomy Strategy combines regulatory, investment and market actions to support sustainable and circular bio-based activity. The Commission plans work on biotechnology, construction-product standards, biomass monitoring, bio-based plastics, public procurement, biogas and biomethane, and industrial symbiosis. It will also establish forums and investment arrangements, support blue-bioeconomy innovation, provide practical guidance for land managers, and pursue international cooperation, stakeholder dialogue and EU-wide monitoring. - [European Biotech Act 1]() — status: in progress. As a cornerstone of the EU’s Life Sciences Strategy, the law will make Europe the most attractive place for biotech by 2030 by speeding approvals and risk assessments without compromising safety, unlocking risk-tolerant finance and biomanufacturing scale, building EU-wide clusters/infrastructure, closing skills gaps, and enabling trusted AI/data use (incl. supercomputing and EHDS links). It tackles single-market fragmentation across health, agri-food, industrial and marine biotech, strengthening competitiveness and economic security. Expected impacts of the law includes faster time-to-market, deeper investment pipelines, resilient supply chains and environmental benefits, supported by strong EU governance. - [European Biotech Act 2]() — status: forthcoming. The proposed European Biotech Act aims to make Europe's health-biotechnology sector more competitive through easier funding, quicker regulatory processes and stronger safeguards. It would support industry, manufacturing and research, especially start-ups and SMEs; facilitate AI, data and digital solutions; simplify rules on clinical trials and cell and gene therapies; and introduce biosecurity measures. The Commission says the Act should help patients gain timelier, broader access to treatments and products. In 2026 it will address the wider biotechnology sector. - [European Centre of Expertise on Research Security]() — status: forthcoming. EU work is underway to establish a Centre of Expertise on Research Security, investing in the evidence base for policymaking and creating a community of practice. It sits alongside a due-diligence platform in development to help universities choose international partners. The Commission presents these measures as support for open but secure research cooperation, responding to risks including foreign interference, malign influence and misuse. - [European Innovation Act]() — status: forthcoming. It will create horizontal, Single-Market-wide conditions to accelerate deployment and diffusion of innovation. The law will (i) simplify and make rules more innovation-friendly (incl. regulatory sandboxes), (ii) unlock IP-backed finance and improve access to EU/national funding, (iii) open research & technology infrastructures to companies, (iv) make public/private procurement more supportive of novel solutions, (v) improve commercialisation of publicly funded R&I (i.e. IP, standardisation, certification), (vi) enable talent attraction/retention (e.g. employee ownership schemes), and (vii) establish EU–Member State coordination of innovation policy, helping to close the EU’s innovation gap. - [European Innovation Council (EIC) Reform]() — status: not recorded. The council will be reformed to operate more strategically and ambitiously, inspired by the US ARPA model. It will shift towards challenge-driven, staged funding for breakthrough, high-risk technologies, focusing on strategic EU priorities and research excellence. The reform will simplify procedures, strengthen the Trusted Investor Network, and build closer ties with Europe’s unicorns to improve policy feedback loops. By combining public and private capital, the EIC will accelerate the scale-up of deep-tech companies in critical sectors and better align innovation funding with Europe’s competitiveness, technological sovereignty, and security objectives. - [European Research Area Act & ERIC Reform]() — status: forthcoming. The Act Act will realise a “fifth freedom” by enabling the free movement of researchers, knowledge and technology across a single EU R&I market, anchored in TFEU Articles 179 and 182(5). It will (1) secure national commitments and new mechanisms to reach the 3% of GDP R&D target; (2) align EU–national investments and priorities around strategic technologies; and (3) upgrade framework conditions—attractive careers and mobility, open science and data access, a stronger legal basis for research infrastructures, and better knowledge valorisation. The Act will safeguard fundamental values, bolster research security, and clarify cooperation with third countries. - [European Strategy for AI in Science]() — status: delivered. Adopted alongside the Apply AI Strategy, this initiative fast-tracks responsible AI uptake across disciplines and builds the foundations of RAISE (i.e. a virtual European institute that pools talent, compute, data and funding for “science for AI” and “AI in science”). It launches Thematic Networks of Excellence and RAISE Doctoral Networks; secures priority access to EuroHPC AI Factories and future AI Gigafactories; and links Data Labs with EOSC and other data spaces. Ethics-by-design guidance and “living” rules govern use, while ERA-based coordination, indicators and summits align Member States and industry. Horizon Europe anchors early actions and an investment agenda for 2026-27. - [European Strategy on Research and Technology Infrastructures]() — status: delivered. The strategy aims to improve Europe's research and technology infrastructure capacity, investment and access. It covers criteria and roadmaps for infrastructures of European interest, funding coordination, upgrades, transnational collaboration and services for startups and scaleups. It also addresses FAIR and AI-ready research data, an enhanced EOSC Federation, coordinated governance, skills, international partnerships, resilience, and trusted storage, processing and sharing of critical data. - [Horizon Europe 2026-2027]() — status: not recorded. The next work programme will channel major investments into Europe’s industrial and scientific transformation. A €600 million flagship call under the Clean Industrial Deal will bridge R&I and deployment, fostering synergies with the Innovation Fund and supporting fusion through new PPPs. In life sciences, the Commission will establish a network of ATMP Centres of Excellence (€4 million), pilot stepwise collaborative health research funding, and invest €50 million in multi-modal genAI for biomedical research. €170 million will support a new health–climate agenda, complemented by global research collaboration and foresight on life sciences skills. - [Quantum Act]() — status: forthcoming. The Act will make the Quantum Europe Strategy operational, fixing fragmentation by aligning EU and national programmes around a shared RTI agenda and targets. It sets EU-level governance and extends the Chips Joint Undertaking’s remit to quantum technologies, coordinating investments across EU programmes. It anchors a three-stage pipeline—Discover; Lab-to-fab via pilot lines, design tools and standards; Apply & use in lead sectors, while scaling pan-European infrastructures in quantum computing, secure communication (EuroQCI) and sensing. The Act backs skills and industrialisation, strengthens supply chains. It also drives standardisation and interoperability and fosters talent attraction. - [Quantum Europe Strategy]() — status: delivered. **Skills.** The Strategy will launch a European Quantum Skills Academy - initially virtual, then networked - linked to Quantum Competence Clusters and Semiconductors Competence Centres. It will host a Quantum Talent Portal, fellowship schemes and “teach-the-teacher” modules to broaden participation and close the gender gap. Complementary actions include a Digital Europe–funded Quantum Apprenticeship pilot and returnships; Advanced Digital Skills Competitions from 2026; an EIC Researchers-in-Residence scheme placing scientists in quantum startups; and a European Quantum Talent Mobility Programme with fellowships for non-EU PhDs and professionals. Skills intelligence will track needs via the European Skills Intelligence Observatory, ensuring training aligns with fast-evolving industrial demand. **Research.** It contains coordinated roadmaps to speed research-to-industry. The Commission will publish an EU Quantum Computing and Simulation Roadmap, a Quantum Chips Industrialisation Roadmap, and a European Quantum Standards Roadmap, while expanding Quantum Competence Clusters to link labs, pilot lines and design facilities. It adds a coordinated European Quantum Sensing, Measurement and Testing Roadmap. To catalyse uptake, the EU will pilot two Grand Challenges (fault-tolerant computing; quantum PNT) and launch a Pilot Programme for Researchers-in-Residence in quantum startups. For dual-use and space, it will deliver a Quantum Technology Roadmap in space with ESA and a Quantum Sensing Space & Defence Technology Roadmap aligning civil-security priorities. **Infrastructure.** The strategy’s infrastructure track will strengthen secure networks, prove platforms, and link civil–defence use. EuroQCI expands 2025–2035 with cross-border terrestrial links, satellite ground stations and EU certification, converging with IRIS² for end-to-end QKD services. In 2026, a pilot European Quantum Internet will test quantum-safe components and early use cases alongside the EU’s post-quantum cryptography roadmap. Europe will deploy ground/airborne gravimeters and prepare a space-gravimetry pathfinder after 2030. A centralised network of open-access quantum testbeds will serve developers, startups and SMEs. An EU-wide Quantum Technology Risk Assessment concludes in 2026. Spin-in initiatives from 2026 accelerate defence uptake. - [RAISE – European AI Research Council]() — status: not recorded. RAISE has entered a pilot phase as the Resource for Artificial Intelligence Science in Europe. The European Commission and the Danish Presidency of the Council of the EU organised the European AI in Science Summit in Copenhagen, where Executive Vice-President Henna Virkkunen and Commissioner Ekaterina Zaharieva announced its launch. --- [Reading guide and interpretation notes]() · [Methodology]()